Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 7;13:7851–7864. doi: 10.2147/OTT.S253485

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Activated HSC-secreted IL-6 confers the SN38 resistance to hypoxic tumor cells. (A) Cell viability assays with LoVo and HCT116 at 48 h after co-culture with the HSC medium or aHSC medium, and 80 nM of SN38 with or without 100 μM of CoCl₂. (B) Flow cytometric analysis of the apoptosis in LoVo and HCT116 cells after 48 h of the indicated treatment. (C) Western blot analysis of the expression level of Bcl-2 and Bax in LoVo and HCT116 cells after 48 h post-treatment. (D) Cell viability assays with LoVo and HCT116 after the co-culture with the HSC medium or aHSC medium and CoCl₂, SN38 and IL-6 neutralizing antibodies. (E) Flow cytometry analysis of the apoptosis in LoVo and HCT116 cells after 48 h of the indicated treatment. (F) Western blot analysis of the expression level of Bcl-2 and Bax in LoVo and HCT116 cells after 48 h of the indicated treatment. N=3; ns, no significant difference; *P<0.05; **P<0.001.